tubulin-specific chaperone A (TBCA): A Promising Drug Target and Biomarker for the Treatment of Neurological Disorders

Target Name: TBCA

NCBI ID: G6902

TBCA

tubulin-specific chaperone A (TBCA): A Promising Drug Target and Biomarker for the Treatment of Neurological Disorders

Introduction

Tubulin-specific chaperone A (TBCA) is a protein that plays a crucial role in the structure and function of microtubules, which are essential components of the cytoskeleton in eukaryotic cells. TBCA is highly conserved across various species, including humans, and has been implicated in various neurological disorders. As a result, it has generated significant interest as a potential drug target or biomarker for the treatment of such disorders. In this article, we will discuss the structure, function, and potential therapeutic applications of TBCA.

Structure and Function

TBCA is a 21-kDa protein that belongs to the family of chaperones, which are a type of protein that can interact with and solubilize microtubules. It is composed of a 156-amino acid residue and has a calculated molecular weight of 19,112. The protein has a unique feature, known as a hypervariable region (HVR), which is involved in its stability and functions.

TBCA functions as a chaperone by interacting with microtubules and helping to maintain their stability. It does this by providing a stable platform for the recruitment of various molecules, including ATP, which is essential for microtubule dynamics. In addition, TBCA can also interact with other proteins that are involved in microtubule function, such as tyrosins and histone proteins.

TBCA has been shown to play a key role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the accumulation of neurofibrillary tangles and the loss of motor and cognitive function.

Potential Therapeutic Applications

TBCA has the potential to serve as a drug target for the treatment of neurological disorders due to its involvement in the development and progression of these disorders. Several studies have shown that modulating TBCA levels or activity can lead to the improvement of cognitive and motor function in animal models of these disorders.

One of the most promising strategies for targeting TBCA is the use of small molecules that can modulate its stability or activity. Several studies have identified compounds that can interact with TBCA and enhance its stability, leading to the formation of more stable microtubules. These compounds have has been shown to improve the cognitive and motor function of animal models of Alzheimer's disease and Parkinson's disease.

Another approach to targeting TBCA is the use of antibodies that can specifically recognize and target the protein. Several studies have shown that antibodies against TBCA can be used to reduce the levels of TBCA in the brain and improve cognitive function in animal models of these disorders.

Conclusion

Tubulin-specific chaperone A (TBCA) is a protein that plays a crucial role in the structure and function of microtubules and has been implicated in various neurological disorders. Its unique feature, the HVR, makes it a potential drug target and biomarker for the treatment of such disorders. Several studies have shown that modulating TBCA levels or activity can lead to the improvement of cognitive and motor function in animal models of these disorders, making TBCA an attractive target for future research.

Protein Name: Tubulin Folding Cofactor A

Functions: Tubulin-folding protein; involved in the early step of the tubulin folding pathway

The "TBCA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBCA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets